Warning: This site requires Javascript to be enabled in order to function as expected.

#smooth-wrapper { height: auto !important; }

Skip to content

Tangram Therapeutics | Committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster.

Press release

Notice of Interim Results

11 October 2021

e-therapeutics plc will announce its interim results for the six months ended 31 July 2021 on Tuesday 26 October 2021.

Enquiries:

e-therapeutics plc

Tel: +44 (0)1993 883 125

Ali Mortazavi, CEO

tangramtx.com

Tags

Share
Sign up for press releases

Discover

Whats New?

Press release

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

Nov 26, 2025

Press release

Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences

Oct 3, 2025

Press release

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Oct 1, 2025

Press release

e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data

Jul 10, 2025

Press release

e-therapeutics presents new data supporting ETX‑312 as a differentiated, disease-modifying near-clinic GalOmic Treatment for MASH

May 7, 2025

Press release

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

Feb 5, 2025

/